Reducing the costs of chronic kidney disease while delivering quality health care: a call to action
Nature Reviews Nephrology 13, 393 (2017).
doi:10.1038/nrneph.2017.63
Authors: Raymond Vanholder, Lieven Annemans, Edwina Brown, Ron Gansevoort, Judith J. Gout-Zwart, Norbert Lameire, Rachael L. Morton, Rainer Oberbauer, Maarten J. Postma, Marcello Tonelli, Wim Van Biesen & Carmine Zoccali
The treatment of chronic kidney disease (CKD) and of end-stage renal disease (ESRD) imposes substantial societal costs. Expenditure is highest for renal replacement therapy (RRT), especially in-hospital haemodialysis. Redirection towards less expensive forms of RRT (peritoneal dialysis, home haemodialysis) or kidney transplantation should decrease financial
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Raymond Vanholder Lieven Annemans Edwina Brown Ron Gansevoort Judith J. Gout-Zwart Norbert Lameire Rachael L. Morton Rainer Oberbauer Maarten J. Postma Marcello Tonelli Wim Van Biesen Carmine Zoccali Tags: Review Source Type: research
More News: Chronic Kidney Disease | Dialysis | Expenditures | Gout | Health Management | Hemodialysis | Hospitals | Kidney Transplant | Kidney Transplantation | Peritoneal Dialysis | Transplants | Urology & Nephrology